Browsing by Author "Alagaratnam J."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    ItemMetadata only
    Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
    (2023-01-13) Fidler S.; Fox J.; Tipoe T.; Longet S.; Tipton T.; Abeywickrema M.; Adele S.; Alagaratnam J.; Ali M.; Aley P.K.; Aslam S.; Balasubramanian A.; Bara A.; Bawa T.; Brown A.; Brown H.; Cappuccini F.; Davies S.; Fowler J.; Godfrey L.; Goodman A.L.; Hilario K.; Hackstein C.P.; Mathew M.; Mujadidi Y.F.; Packham A.; Petersen C.; Plested E.; Pollock K.M.; Ramasamy M.N.; Robinson H.; Robinson N.; Rongkard P.; Sanders H.; Serafimova T.; Spence N.; Waters A.; Woods D.; Zacharopoulou P.; Barnes E.; Dunachie S.; Goulder P.; Klenerman P.; Winston A.; Hill A.V.S.; Gilbert S.C.; Carroll M.; Pollard A.J.; Lambe T.; Ogbe A.; Frater J.; Mahidol University
    BACKGROUND: People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) with good CD4 T-cell counts make effective immune responses following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are few data on longer term responses and the impact of a booster dose. METHODS: Adults with HIV were enrolled into a single arm open label study. Two doses of ChAdOx1 nCoV-19 were followed 12 months later by a third heterologous vaccine dose. Participants had undetectable viraemia on ART and CD4 counts >350 cells/µL. Immune responses to the ancestral strain and variants of concern were measured by anti-spike immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA), MesoScale Discovery (MSD) anti-spike platform, ACE-2 inhibition, activation induced marker (AIM) assay, and T-cell proliferation. FINDINGS: In total, 54 participants received 2 doses of ChAdOx1 nCoV-19. 43 received a third dose (42 with BNT162b2; 1 with mRNA-1273) 1 year after the first dose. After the third dose, total anti-SARS-CoV-2 spike IgG titers (MSD), ACE-2 inhibition, and IgG ELISA results were significantly higher compared to Day 182 titers (P < .0001 for all 3). SARS-CoV-2 specific CD4+ T-cell responses measured by AIM against SARS-CoV-2 S1 and S2 peptide pools were significantly increased after a third vaccine compared to 6 months after a first dose, with significant increases in proliferative CD4+ and CD8+ T-cell responses to SARS-CoV-2 S1 and S2 after boosting. Responses to Alpha, Beta, Gamma, and Delta variants were boosted, although to a lesser extent for Omicron. CONCLUSIONS: In PWH receiving a third vaccine dose, there were significant increases in B- and T-cell immunity, including to known variants of concern (VOCs).
  • No Thumbnail Available
    ItemMetadata only
    Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
    (2022-04-08) Ogbe A.; Pace M.; Bittaye M.; Tipoe T.; Adele S.; Alagaratnam J.; Aley P.K.; Ansari M.A.; Bara A.; Broadhead S.; Brown A.; Brown H.; Cappuccini F.; Cinardo P.; Dejnirattisai W.; Ewer K.J.; Fok H.; Folegatti P.M.; Fowler J.; Godfrey L.; Goodman A.L.; Jackson B.; Jenkin D.; Jones M.; Longet S.; Makinson R.A.; Marchevsky N.G.; Mathew M.; Mazzella A.; Mujadidi Y.F.; Parolini L.; Petersen C.; Plested E.; Pollock K.M.; Rajeswaran T.; Ramasamy M.N.; Rhead S.; Robinson H.; Robinson N.; Sanders H.; Serrano S.; Tipton T.; Waters A.; Zacharopoulou P.; Barnes E.; Dunachie S.; Goulder P.; Klenerman P.; Screaton G.R.; Winston A.; Hill A.V.S.; Gilbert S.C.; Carroll M.; Pollard A.J.; Fidler S.; Fox J.; Lambe T.; Frater J.; Mahidol University
    Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.